Skip to main content

Advertisement

Table 3 Number of adverse events reported in ≥ 5% of subjects by treatment group

From: Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial

AE description Synvisc-One n = 32 Hydros n = 32 Hydros-TA n = 34
Any TEAE, n (%) 23 (72) 24 (75) 21 (62)
Arthralgia, n (%) 8 (25) 11 (34) 7 (21)
Joint Swelling, n (%) 2 (6) 3 (9) 2 (6)
Joint Stiffness, n (%) 2 (6) 3 (9) 0
Back Pain, n (%) 3 (9) 1 (3) 1 (3)
Muscle Spasms, n (%) 1 (3) 0 3 (9)
Arthritis, n (%) 0 2 (6) 0
Headache, n (%) 8 (25) 6 (19) 4 (12)
Nasopharyngitis, n (%) 3 (9) 1 (3) 1 (3)
Nausea, n (%) 1 (3) 2 (6) 1 (3)
Meniscus Lesion, n (%) 1 (3) 0 2 (6)
Tendon Pain, n (%) 2 (6) 0 0
  1. Abbreviations: AE = Adverse Event; TEAE = Treatment-Emergent Adverse Event.